Eton Pharmaceuticals, Inc.
ETON Nasdaq
SEC CIK 1710340
Follow Eton Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$57.9M
+157.9% vs same quarter last year
Net income
$35.2M
+1929.2% vs same quarter last year
EPS, diluted
$1.06
+1614.3% vs same quarter last year
Operating cash flow
$35.2M
+193% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $80M | −$4.6M |
| FY24 | $39M | −$3.8M |
| FY23 | $31.6M | −$936K |
| FY22 | $21.3M | −$9M |
| FY21 | $21.8M | −$2M |
| FY20 | $39K | −$28M |
| FY19 | $959K | −$18.3M |
| FY18 | - | −$12.7M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 53.5% | −1.1% | −5.8% |
| FY24 | 60% | −6.7% | −9.8% |
| FY23 | 66.6% | −3.8% | −3% |
| FY22 | 67.4% | −38.9% | −42.4% |
| FY21 | 87.1% | −6.8% | −9% |
| FY20 | −1017.9% | −69515.4% | −71717.9% |
| FY19 | 52.8% | −1939.6% | −1910.3% |
| FY18 | - | - | - |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $10.2M |
| FY24 | $943K |
| FY23 | $6.8M |
| FY22 | $4.8M |
| FY21 | −$4.7M |
| FY20 | −$22.4M |
| FY19 | −$19.1M |
| FY18 | −$8.4M |
| FY17 | - |
- Eton Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Eton Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −5.8% | −30.6% |
| FY24 | −9.8% | −47% |
| FY23 | −3% | −58% |
| FY22 | −42.4% | −80.4% |
| FY21 | −9% | −71.8% |
| FY20 | −71717.9% | −62.2% |
| FY19 | −1910.3% | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |